An observational study in Non-Infectious Active Uveitis, sponsored by University Hospital, Bordeaux. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by University Hospital, Bordeaux · Observational
The study aims at defining the role of soluble CD95 Ligand in the physiopathology of the non-infectious uveitis. Soluble CD95 Ligand might have a prognostic interest as well as potential for the discovery of new therapeutic strategies
Non-Infectious active uveitis is a severe inflammatory ocular disease which can expose to the blindness. Actually, the knowledge of the physiopathology of uveitis stay poorly. CD95 Ligand (CD95-L) belongs to a TNF (tumor necrosis factors) receptor family. It knows to play a preponderant role to maintain the eye immune privilege. In particular conditions depending on immunologic environment, CD95-L has pro-inflammatory properties and can interact with Th17 lymphocytes and neutrophils, two cells implicated in non-infectious uveitis. The hypothesis is that s-CD95-L levels might be a prognostic factor in non-infectious uveitis and the study of the molecular mechanisms involved could provide new therapeutic targets.
This study will recruit 100 patients with non-infectious uveitis followed in Bordeaux University Hospital. Among classical disease activity information, blood samples will be collected during to assess s-CD95-L. Fundamental research will be realized on patients' sample to evaluate underlying molecular mechanisms.
Clinical and biological disease activity, treatment and outcomes will be studied in correlation with s-CD95-L to describe their potential prognostic role. Patients will be followed at regular intervals, accordingly to usual care.
335 studies on the registry are indexed under Uveitis; 37 are open to participants now.
This study's enrollment of 20 is below the median of 100 across 107 observational studies indexed under Uveitis.
Browse Uveitis studies →University Hospital, Bordeaux is the lead sponsor of 783 studies on the registry; 188 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with non-infectious uveitis
Exclusion Criteria:
levels of s-CD95-L (ELISA test)
Other: s-CD95-L
levels of s-CD95-L (ELISA test)
levels of s-CD95-L
levels of s-CD95-L (ELISA test) in sera of non-infectious uveitis patients
Time frame: Baseline
Correlation between levels of s-CD95-L and Disease activity score
Correlation between levels of s-CD95-L and Disease activity score (as defined by ophthalmologic examination)
Time frame: Baseline, Month 3
Th17 dosage
Th17 dosage
Time frame: Baseline, Month 3
polynuclear neutrophils levels
polynuclear neutrophils levels (Flow cytometry)
Time frame: Baseline, Month 3
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux